Sterile workspace for preparation of RNA & DNA samples
![](/46/pdcnewsitem/03/79/53/cleaverscientificpr10-image.jpg)
Cleaver Scientific has supplied a UV Sterilization Cabinet to Touchlight Genetics (Hampton, UK) who had sought a sterile workspace for the preparation of their RNA and DNA samples and templates.
Touchlight Genetics is a rapidly expanding UK biotech company that has developed an entirely enzymatic process of DNA synthesis that is fast, efficient and has a yield that can easily meet growing demand for DNA. The company's dbDNA expression cassettes eliminate the need for bacterial sequences and antibiotic resistance genes in the production of biological therapies, satisfying stated concerns from the industry’s main regulatory bodies (FDA and EMA). This novel technology promises to provide a near-term manufacturing solution to a key bottleneck in the production of innovative therapies.
Commenting on the implementation of the UV sterilisation cabinet in their laboratories, Dr Lydia Hunter, a research scientist at Touchlight Genetics said: "We have made good use of our UV Sterilisation Cabinet from Cleaver Scientific, which enables us to prepare our RNA and DNA samples and templates in a clean, safe and contained environment. Touchlight Genetics would highly recommend this product and Cleaver Scientific as a supplier as their customer service has been excellent. Cleaver Scientific has been extremely supportive in ensuring their product is well maintained and meets our requirements."
The CleanView range of UV Sterilisation Cabinets from Cleaver Scientific, provide a sterile contained environment for the preparation and manipulation of sensitive biological samples. Acting as a low cost alternative to a clean room, powerful UV lights in the cabinet are used to denature nucleic acids in 5 to 30 minutes making them unsuitable for amplification. White light provides excellent visibility when working within the cabinet.
Cleaver UV sterilisation cabinets incorporate safety features to prevent user exposure to UV light; the UV lights are timer controlled, and there are safety switches on the cabinets doors which automatically turn the UV lights off when opened. The cabinet also acts as an efficient shield from radioactive beta emissions, and can therefore be safely used with isotopes such as 32P.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance